Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr-Jun;22(2):164-73.
doi: 10.4103/0974-9233.154389.

Novel pharmacotherapies in diabetic retinopathy

Vaidehi S Dedania  1 , Sophie J Bakri  2
Affiliations
Review

Novel pharmacotherapies in diabetic retinopathy

Vaidehi S Dedania et al. Middle East Afr J Ophthalmol. 2015 Apr-Jun.

Abstract

This is a summary of current and emerging pharmacologic therapies utilized in the treatment of diabetic retinopathy (DR). Current therapies, such as ranibizumab, bevacizumab, triamcinolone acetonide, and fluocinolone acetonide, inhibit angiogenesis and inflammation and may be used alone or in combination with laser treatment. Emerging therapies aim to reduce oxidative stress or inhibit other signal transduction pathways, including the protein kinase C cascade and aldose reductase pathway. Future therapies may target other molecules crucial to the pathogenesis of DR, including hepatocyte growth factors and matrix metalloproteinase 9. Finally, the emergence of novel mechanisms of medication delivery may also be on the horizon.

Keywords: Corticosteroids; Diabetic Retinopathy; Eye; Intravitreal Injection; Treatment; Vascular Endothelial Growth Factor.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Ruigómez A, García Rodríguez LA. Presence of diabetes related complication at the time of NIDDM diagnosis: An important prognostic factor. Eur J Epidemiol. 1998;14:439–45. - PubMed
    1. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91:1–9. - PubMed
    1. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol. 1995;113:36–51. - PubMed
    1. The Diabetes Control and Complications Trial. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342:381–9. - PMC - PubMed
    1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–53. - PubMed

MeSH terms